EYE 2.17% 22.5¢ nova eye medical limited

Nova Eye Medical (EYE) Discussion, page-898

  1. 1,715 Posts.
    lightbulb Created with Sketch. 195
    Interesting. I do note in the limitations two things:
    1. in the canaloplasty group, there was a higher number of secondary glaucoma patients, but no mention of the percentage. What if over half were? Seems to be quite a serious limitation to the results.
    2. A large number of patients that had the canaloplasty surgery did not return for the follow-up check (likely due to success and no complications), and then removed from the study - resulting a lower percentage of success. I believe it was 30 - if 20 had been successful, the whole thesis is weakened considerably.

    Let me know if I have misunderstood the impact of those limitations of the study.
    Last edited by BuffettWarren: 12/07/23
 
watchlist Created with Sketch. Add EYE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.